http://bit.ly/2MxjVZA



points form the article:



- 2 biotech firms investing $228M to open plants in Puerto Rico



- CytoImmune Therapeutics, Inc. and Biosimilar Solutions, LLC will establish operations in Puerto Rico to develop their biotechnology products.



- Biosimilar Sciences will work on biotech products, including a COVID-19 vaccine.



- Biosimilar’s current product portfolio has an approximate market value of $30 billion.



- Puerto Rico who helped make our presence here possible have been supportive, a reflection of the island’s commitment to performing on the highest level in terms of life science manufacturing and business development,



- Puerto Rico Incentives Code (Act 60) and other assets to set up their operations.